Today's Health Winners and Losers
Shares of Amedisys (AMED) were among the worst-performing health-related stocks Thursday, tumbling 24% after the home-health nursing company posted fourth-quarter earnings that were well below forecasts and announced the resignation of its chief financial officer.
The company earned $7.3 million, or 45 cents a share, on service revenue of $118.9 million. Analysts surveyed by Thomson First Call expected earnings of 55 cents a share on revenue of $117.9 million. During the year-earlier period, the company earned $6.1 million, or 39 cents a share, on sales of $64.4 million. Amedisys blamed the weak fourth-quarter earnings on the "transitional cost and delayed timeline expectations for performance improvement from the recent acquisitions of Housecall and Spectracare, the as yet unrealized synergies from the reduction in Housecall's corporate office expenses and the residual impact of last summer's hurricanes."
For 2006, Amedisys continues to predict earnings of $2.33 to $2.43 a share, with sales of $510 million. Analysts project earnings of $2.42 a share on sales of $516 million.
Amedisys said CFO Gregory Browne resigned to pursue other opportunities. The company has hired a search firm to aid it in finding a successor. Browne, meanwhile, will continue to serve as CFO until a replacement is found and transitioned, the company said. Shares were trading down $9.80 to $30.80.GTC Biotherapeutics (GTCB) shares plunged 39% after the biopharmaceutical company said an advisory committee of the European Medicines Agency plans to issue a negative opinion related to the company's application for ATryn, a recombinant form of human antithrombin. "On the basis of recent conversations, GTC understands that the CHMP, after excluding data from pregnant patients, determined that an insufficient number of surgical patients were enrolled to support approval," the company said in a statement. GTC said it plans to use the appeals process to ask the agency to re-examine the application. Shares were trading down 87 cents to $1.38. Nearly 21 million shares have changed hands, compared with an average daily volume of just 764,219 shares.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV